Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | MITF | O75030 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13310961 | 0.85 | KMT2A (0.46) | KMT2AALDH1A1L3MBTL1LMNAGAA | |
| Hydrochloric Acid SCHEMBL2332778 | 0.83 | KMT2A (0.62) | KMT2AALDH1A1L3MBTL1LMNAGAA | |
| SCHEMBL14210319 | 0.81 | KMT2A (0.43) | KMT2AALDH1A1L3MBTL1LMNAGAA | |
| SCHEMBL2334286 | 0.81 | KMT2A (0.47) | KMT2AALDH1A1L3MBTL1LMNAGAA | |
| Hydrochloric Acid SCHEMBL2330352 | 0.81 | KMT2A (0.69) | KMT2AALDH1A1L3MBTL1LMNAGAA | |
| Hydrochloric Acid SCHEMBL2330965 | 0.80 | KMT2A (0.71) | KMT2AALDH1A1L3MBTL1LMNAGAA | |
| SCHEMBL13310957 | 0.80 | ALDH1A1 (0.55) | KMT2AALDH1A1L3MBTL1LMNAGAA | |
| SCHEMBL13347784 | 0.77 | KMT2A (0.42) | KMT2AALDH1A1L3MBTL1LMNAGAA | |
| SCHEMBL12445241 | 0.76 | ALDH1A1 (0.50) | KMT2AALDH1A1L3MBTL1LMNAGAA | |
| SCHEMBL13310979 | 0.75 | KMT2A (0.63) | KMT2AALDH1A1L3MBTL1LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160067257-A1 | SCREENING METHOD AND COMPOUNDS FOR MODULATING TELOMERASE ACTIVITY | THE WISTAR INSTITUTE (US) | 2016-03-10 | — | — | US | disclosed |
| US-20160067257-A1 | SCREENING METHOD AND COMPOUNDS FOR MODULATING TELOMERASE ACTIVITY | THE WISTAR INSTITUTE (US) | 2016-03-10 | — | — | US | disclosed |
| US-20160067257-A1 | SCREENING METHOD AND COMPOUNDS FOR MODULATING TELOMERASE ACTIVITY | THE WISTAR INSTITUTE (US) | 2016-03-10 | — | — | US | disclosed |
| US-9234230-B2 | Screening method and compounds for modulating telomerase activity | THE WISTAR INSTITUTE (US) | 2016-01-12 | — | — | US | disclosed |
| US-8518940-B2 | FP-pocket-binding effectors and methods for using the same to modulate telomerase activity | THE WISTAR INSTITUTE (US) | 2013-08-27 | — | — | US | disclosed |
| US-8518940-B2 | FP-pocket-binding effectors and methods for using the same to modulate telomerase activity | THE WISTAR INSTITUTE (US) | 2013-08-27 | — | — | US | disclosed |
| US-8518940-B2 | FP-pocket-binding effectors and methods for using the same to modulate telomerase activity | THE WISTAR INSTITUTE (US) | 2013-08-27 | — | — | US | disclosed |
| US-20120309759-A1 | Screening Method and Compounds for Modulating Telomerase Activity | THE WISTAR INSTITUTE (US) | 2012-12-06 | — | — | US | disclosed |
| WO-2011097600-A1 | SCREENING METHOD AND COMPOUNDS FOR MODULATING TELOMERASE ACTIVITY | THE WISTAR INSTITUTE (US) | 2011-08-11 | — | — | WO | disclosed |
| US-20100158798-A1 | FP-Pocket-Binding Effectors and Methods for Using the Same to Modulate Telomerase Activity | THE WISTAR INSTITUTE | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309759-A1 | Screening Method and Compounds for Modulating Telomerase Activity | TERT, TERB1, TERF2 | KMT2A 2921/4885ALDH1A1 3360/4885L3MBTL1 348/4885 |
| US-20100158798-A1 | FP-Pocket-Binding Effectors and Methods for Using the Same to Modulate Telomerase Activity | TERF2IP, TERF2, TERT | KMT2A 2483/4885ALDH1A1 4190/4885L3MBTL1 255/4885 |
| US-20160067257-A1 | SCREENING METHOD AND COMPOUNDS FOR MODULATING TELOMERASE ACTIVITY | TERT, TERB1, TERF2 | KMT2A 2921/4885ALDH1A1 3360/4885L3MBTL1 348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.